Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
CLAREMONT, Calif., Nov. 22, 2016 -- Kiwa Bio-Tech Products Group Corporation (OTCQB:KWBT). On November 21, 2016, Kiwa Bio-Tech Products Group Corporation ("Kiwa" or the “Company”) reported its operating results for its third quarter ended September 2016. For the third quarter, Kiwa reported revenue of $1,261,544 and net income of $93,601. For the nine months ended September 30, 2016, Kiwa reported revenue of $1,971,639 and net income of $331,707.
Kiwa also reported that its wholly-owned subsidiary, Kiwa Bio-Tech (Beijing) Co., LTD, has been granted the required sales permit for fertilizers issued by the Chinese government. As a result, it projects US$8,000,000 in 4th quarter sales of fertilizers in China.
Mr. Xiaoqiang Yu, sales director of the Company, said that ‘‘once Kiwa (Beijing) obtained the required Chinese fertilizer sales license, Kiwa (Beijing) can expect sales of nearly 40,000 tons of fertilizer products in the fourth quarter, which includes sales to both existing and new customers”. Mr. Yu also said that the peak season for sales of fertilizer in China is generally the fourth quarter. “Now that we have the fertilizer sales permit, we are now able to transition our sales from our prior sales agent to Kiwa (Beijing)."
For more information on Kiwa and its products, please refer to the Company’s website at www.kiwabiotech.com or the Company filings with the United States Securities and Exchange Commission, available for free at www.sec.gov.
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the U.S. Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
CONTACT: Kiwa Bio-Tech Products Group Corporation Yvonne Wang [email protected]
